San Diego-centered Viking Therapeutics marked by itself as a serious competitor from the weight loss drug sector in February soon after revealing promising facts from the mid-phase trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when supplied to be a weekly injection and in March the company unve